MAINZ, GERMANY, and SHANGHAI, CHINA, December 16, 2020 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) today announced an agreement to supply Mainland China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval. Initial supply will be delivered from BioNTech’s production facilities in Germany.
In response to Guo’s comments, Chuang Jen-hsiang, a spokesman for Taiwan’s Central Epidemic Command Center, said that the government had spoken directly to all vaccine providers including BioNTech. “There is no message from BioNTech to us saying that we should talk to Fosun instead,” he said.
Taiwan has already signed off on a supply deal with BioNTech, it’s just waiting for the company to respond, Chuang said.
On March 13, 2020, Fosun Pharma became the strategic partner of BioNTech in China, jointly developing and commercializing vaccine products for COVID-19 based on its proprietary mRNA technology platform in Mainland China, Hong Kong and Macau Special Administration Region and the Taiwan Region. Since the collaboration between the two sides, Fosun Pharma has been deeply involved in the research and development of mRNA vaccines. In addition to comprehensively and deeply discussing the research and development plans with partners and completing clinical trials in China, Fosun Pharma has also designed and completed animal challenge trials of selected mRNA vaccines, including BNT162b2, in collaboration with Chinese research institutes, and shared outcomes with partners in a timely manner.
只要不停補貼假私企買曬d台灣必須品既亞洲/大中華地區獨家代理權，就斷曬台灣必須品
學之前cctoy班人講咁，外國企業唔會為左台灣而毀約影響自己利益